Antidiabetic medications and obesity

The relationship between type 2 diabetes mellitus and obesity is not merely an epidemiological coexistence, but an extremely close pathophysiological relationship that affects diagnosis, disease progression, therapeutic response, and cardiovascular, renal, and hepatic prognosis. In the vast majority of patients with type 2 diabetes mellitus, excess adipose tissue, especially visceral and ectopic fat, is one of the main determinants of insulin resistance, initial compensatory hyperinsulinemia, progressive beta-cell exhaustion, and amplification of chronic low-grade inflammation. For this reason, in modern diabetology, medication selection can no longer be based solely on the ability to lower glycated hemoglobin, but must explicitly consider the effect on body weight, fat distribution, appetite, hypoglycemia risk, and the possibility of achieving a lasting improvement in the overall cardiometabolic profile.

Obesity affects a very large proportion of people with type 2 diabetes mellitus, and its treatment profoundly changes the entire clinical strategy. Even moderate weight loss can improve glycemic control and reduce treatment requirements, whereas more substantial weight loss, especially in the early stages of the disease, may promote metabolic remission in a proportion of selected patients. From this perspective, antidiabetic medications are not all equivalent. Some promote clinically meaningful weight loss, others are essentially weight-neutral, and still others tend to promote weight gain and may therefore counteract one of the central goals of treatment. Understanding these effects does not mean reasoning in aesthetic or ancillary terms, but rather acting on a causal driver of type 2 diabetes mellitus.

For many years, the management of type 2 diabetes mellitus was based on an almost exclusively glucose-centric model, in which therapeutic success was assessed primarily by reductions in blood glucose and glycated hemoglobin. This approach remains important, but is now clearly insufficient. Excess adiposity, in fact, acts not only as an initial risk factor, but as a persistent biological driver of the disease. Visceral adipose tissue increases the flux of free fatty acids to the liver, promotes hepatic steatosis, increases hepatic glucose production, impairs skeletal muscle insulin sensitivity, and contributes to altered secretion of adipokines and proinflammatory mediators. At the same time, ectopic fat deposition in the pancreas has been associated with deterioration of beta-cell function.

This sequence leads to an essential clinical principle: treating obesity in a patient with type 2 diabetes mellitus means acting not only on a comorbidity, but on one of the mechanistic foundations of the disease. This is why the modern literature increasingly refers to a weight-centric approach, centered on weight, without denying the need for glycemic control but integrating it into a broader perspective. When weight is reduced to a clinically significant extent, fasting glucose, postprandial glucose, blood pressure, hepatic steatosis, obstructive sleep apnea, mobility, quality of life, and overall cardiovascular risk often improve.

The clinical significance of weight loss, however, depends on its magnitude. A loss of 5% of initial body weight is already associated with measurable metabolic improvements, but greater benefits are generally observed with larger reductions. In people with recent-onset diabetes and obesity, more substantial weight loss can reduce glucotoxicity and lipotoxicity sufficiently to promote substantial normalization of glucose metabolism. This explains why, in a person with type 2 diabetes mellitus and obesity, the appropriate clinical question is not simply which medication lowers glycated hemoglobin most effectively, but which treatment provides the best balance among glycemic control, weight loss, safety, and organ protection.

Pharmacological treatment must be individualized, but several general principles in patients with obesity are now strongly supported by international guidelines. First, whenever possible, preference should be given to agents that lower blood glucose without promoting weight gain. Second, in the presence of overweight or obesity, especially when clinically significant, medications with a favorable effect on weight should be preferred, particularly when the patient has increased hunger, excessive caloric intake, marked visceral adiposity, metabolic dysfunction-associated steatotic liver disease, or a need to reduce insulin requirements. Third, medications associated with weight gain are not “prohibited,” but they should be used with clear clinical justification and with measures designed to limit metabolic harm.

This approach requires moving beyond a rigid stepwise logic and reasoning according to clinical phenotypes. A young patient with recently diagnosed diabetes, severe obesity, and no catabolic features often derives the greatest benefit from strategies targeting appetite, energy intake, and insulin resistance. A patient with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease may require choices in which the effect on weight is integrated with cardiorenal protection. Conversely, an older patient with frailty or sarcopenia should not be managed with an indiscriminate weight-loss goal, because loss of lean mass may become clinically more dangerous than excess fat.

The initial assessment should therefore include not only body mass index, but also waist circumference, weight trajectory over time, fat distribution, signs of dysfunctional hunger, level of physical activity, diet quality, possible binge eating, current treatments, hypoglycemia risk, kidney function, presence of metabolic dysfunction-associated steatotic liver disease, heart failure, sleep apnea, and musculoskeletal limitations. In other words, body weight is not merely a background measurement, but a guiding parameter that must inform medication selection from the outset of the therapeutic pathway.

Expected effect on body weight of the main medication classes

• Greatest weight loss: glucagon-like peptide 1 receptor agonists and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonists
• Modest weight loss: sodium-glucose cotransporter 2 inhibitors, metformin
• Weight-neutral or tending to cause weight gain: dipeptidyl peptidase 4 inhibitors, acarbose, thiazolidinediones, insulin secretagogues, insulin

Among antidiabetic medications with a favorable profile in patients with obesity, metformin retains a central role, especially in the early stages of type 2 diabetes mellitus. Its effect on weight is generally modest but clinically useful because it tends to be neutral or mildly weight-reducing, unlike medications that promote weight gain. This profile results from a combination of mechanisms, including reduced hepatic glucose production, improved insulin sensitivity, possible modulation of intestinal absorption, and an indirect effect on appetite in some patients. Metformin alone rarely produces dramatic weight loss, but it often provides a solid metabolic foundation on which to build combinations that are more effective for weight reduction.

A paradigm shift occurred with glucagon-like peptide 1 receptor agonists and, subsequently, with dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonists. These agents not only stimulate glucose-dependent insulin secretion and reduce glucagon secretion, but also exert substantial effects on eating behavior. They slow gastric emptying to varying degrees, increase satiety, reduce food reward, and facilitate a reduction in energy intake. The clinical result is markedly greater weight loss than with most traditional antidiabetic medication classes. In people with obesity and type 2 diabetes mellitus, this effect is not secondary, but often represents the main reason why these medications alter the trajectory of the disease.

Within this therapeutic area, there are quantitative differences. Anti-obesity doses of semaglutide and tirzepatide have shown particularly substantial weight reductions, with parallel improvements in glycated hemoglobin, waist circumference, and other cardiometabolic markers. This makes these options extremely attractive in patients with clinically significant obesity, especially when glycemic control can still be restored without insulin or when the aim is to reduce an insulin regimen already in use. It should be remembered, however, that the effect depends not only on pharmacological potency, but also on gastrointestinal tolerability, appropriate titration, long-term adherence, and integration with a structured nutritional program.

Sodium-glucose cotransporter 2 inhibitors produce more modest but often useful weight loss, achieved mainly through glycosuria and urinary caloric loss. Their advantage in patients with type 2 diabetes mellitus and obesity is twofold. On the one hand, they produce a generally modest but sustained reduction in weight; on the other, they provide major cardiorenal benefits in selected subgroups. Their effect on weight predominantly involves fat mass, particularly visceral fat, although the literature has drawn attention to the possible concomitant loss of lean mass in some patients, an aspect that warrants caution in older, malnourished, or sarcopenic individuals.

Overall, when obesity is a substantial component of the clinical problem, the modern hierarchy of treatment choices tends to favor medications that reduce both blood glucose and weight. This does not mean that all patients should receive the same medication, but the weight penalty of some older strategies can no longer be disregarded as a marginal detail.

Some antidiabetic medication classes have an overall weight-neutral or only minimally favorable effect. Dipeptidyl peptidase 4 inhibitors are the paradigm. These medications enhance endogenous incretin signaling, but much less intensively than receptor agonists and generally without producing an appreciable weight-loss effect. In practical terms, they are well tolerated, easy to use, and associated with a low risk of hypoglycemia when not combined with insulin secretagogues or insulin; however, their limitation is evident in patients with severe obesity: they control blood glucose without substantially affecting the adiposity-related pathophysiological driver.

This weight neutrality may nevertheless be useful in certain settings. An older patient with mild hyperglycemia, a need for treatment simplification, and poor gastrointestinal tolerance of incretin receptor agonists may benefit from a strategy that does not cause further weight gain, although weight loss should not be expected. Similarly, acarbose and some other more selectively used medications may be considered essentially weight-neutral or mildly favorable, but their current role is far less central than that of newer classes.

The clinically relevant point is that weight neutrality is not equivalent to a weight benefit. In a patient with marked visceral obesity, fatty liver, a strong drive to eat, and a need to reduce cardiometabolic risk, a weight-neutral medication may be metabolically insufficient even if it lowers glycated hemoglobin. In this population, therapeutic reasoning should shift toward agents capable of more substantially modifying energy balance and fat accumulation.

Antidiabetic medications associated with weight gain should not automatically be avoided, but they require careful assessment of the benefit-risk balance in patients with obesity. Sulfonylureas and meglitinides, by increasing insulin secretion relatively independently of behavioral context and with a higher hypoglycemia risk than newer classes, tend to promote weight gain through at least three mechanisms: increased insulin-mediated anabolism, reduced glycosuria, and greater compensatory caloric intake to prevent or treat hypoglycemia. In a patient who is already obese, this trajectory may reinforce insulin resistance and worsen the underlying metabolic profile.

Thiazolidinediones, particularly pioglitazone, present a more complex situation. They improve insulin sensitivity and may have a useful role in specific metabolic phenotypes, including metabolic dysfunction-associated steatohepatitis in selected patients, but they are often accompanied by weight gain. This increase partly reflects adipose tissue remodeling, with redistribution of fat toward compartments that are less harmful than visceral fat, but also fluid retention and possible expansion of extracellular volume. Pioglitazone is contraindicated in patients with current or prior heart failure; obesity, edema, or fracture risk nevertheless makes it a particularly unfavorable choice.

Insulin remains a fundamental and, in many cases, irreplaceable therapy, particularly when catabolism, symptoms of severe hyperglycemia, marked beta-cell secretory depletion, long-standing disease, or failure of other options predominate. However, in type 2 diabetes mellitus with obesity, insulin therapy is often accompanied by weight gain. The reasons are pathophysiologically consistent: reduced urinary caloric loss, anabolic action, correction of glucose and lipid catabolism, and the possible need to consume more calories to prevent hypoglycemia. The more intensive the insulin regimen and the higher the total dose, the more clinically relevant the risk of weight gain tends to become.

This does not imply that insulin should be avoided when indicated. Rather, it means that when insulin is introduced in a patient with obesity, a weight-mitigation strategy should be planned from the outset, for example by continuing metformin whenever possible, adding medications with weight-reducing or at least weight-neutral effects, reducing hypoglycemia, avoiding overinsulinization, and working simultaneously on nutrition, physical activity, and periodic dose review.

In clinical practice, treatment should be constructed around an essential question: is obesity merely an associated comorbidity, or does it represent the primary therapeutic target in the specific case? In many patients with type 2 diabetes mellitus, the latter is correct. When excess weight is marked, appetite is increased, the patient has a history of repeated dietary failures, and glycated hemoglobin is not extremely high, early use of medications with a major effect on weight is often more rational than progressively adding agents that lower blood glucose without modifying the biological context that generates hyperglycemia.

A patient with obesity and atherosclerotic cardiovascular disease may derive particular benefit from incretin receptor agonists with documented cardiovascular benefit, whereas in a patient with heart failure or chronic kidney disease, sodium-glucose cotransporter 2 inhibitors have a specific value that extends beyond weight loss. In people with metabolic dysfunction-associated steatotic liver disease, selecting medications that promote weight loss and improve insulin sensitivity acquires additional significance. In a patient with severe obesity and still relatively early diabetes, substantial weight reduction may instead become a goal for metabolic remission and treatment de-escalation.

There are also situations in which the priority is not the greatest possible weight loss, but the appropriate balance between efficacy and preservation of lean mass. In frail older adults, patients with sarcopenia, severely obese sedentary individuals with poor muscle strength, or patients with cancer, weight loss should not be pursued indiscriminately. In these cases, the clinician must distinguish reduction of pathological fat from undesirable loss of muscle mass, because worsening body composition may translate into greater disability, more falls, and reduced independence.

Finally, combination therapy is a fundamental consideration. In patients treated with insulin, combination with metformin, glucagon-like peptide 1 receptor agonists, dual incretin receptor agonists, or sodium-glucose cotransporter 2 inhibitors may reduce insulin requirements and limit weight gain. This approach is often more consistent with pathophysiology than simply intensifying insulin progressively, especially when the dominant problem remains adiposity-related insulin resistance.

One of the most common errors in managing patients with obesity and type 2 diabetes mellitus is assessing therapeutic efficacy solely by the number on the scale. Weight remains a useful indicator, but it does not fully define the problem. Clinically, it also matters which tissue is lost, how rapidly, how sustainably, and with what effects on hunger, blood glucose, blood pressure, hepatic steatosis, and daily functioning. Incretin receptor agonists and dual incretin agents tend to produce the greatest weight loss, predominantly through fat reduction, but may also be accompanied by some loss of lean mass; this requires integration with resistance exercise and adequate protein intake.

Sodium-glucose cotransporter 2 inhibitors promote more limited weight loss, which is often useful but rarely sufficient on its own in severe obesity. Part of the initial reduction may reflect changes in fluid balance, whereas over the long term the reduction in fat mass, particularly visceral fat, is more important. Metformin generally produces more modest effects, but has the advantage of not hindering weight goals and can be continued in many combinations. By contrast, insulin secretagogues and insulin can markedly improve blood glucose while increasing weight, making it necessary to interpret metabolic improvement in light of the pathophysiological price paid in terms of additional adiposity.

The other central issue is sustainability. A medication that induces rapid weight loss but is discontinued early because of nausea, vomiting, cost, poor adherence, or unrealistic expectations may produce worse results than a less aggressive but stable strategy. Therapeutic success is therefore determined not only by an agent's maximum theoretical effect, but by its realistic integration into the patient's life, follow-up, and long-term treatment plan.

During follow-up of patients with type 2 diabetes mellitus and obesity, weight assessment should be systematic but not mechanical. The weight trend, rather than a single isolated measurement, should be recorded, and interpretation should be integrated with waist circumference, glycated hemoglobin, home glucose measurements, blood pressure, kidney function, liver enzymes, any reduction in the need for other medications, and treatment tolerability. In patients treated with incretin receptor agonists or dual incretin agents, gastrointestinal symptoms, titration rate, hydration, and diet quality should be monitored carefully, because weight loss achieved at the cost of inadequate protein intake or prolonged poor tolerability may be clinically suboptimal.

In people treated with sodium-glucose cotransporter 2 inhibitors, hydration status, genitourinary infections, ketosis in predisposing situations, and, in more vulnerable patients, possible indirect signs of excessive lean-mass loss should be monitored. In patients receiving insulin or insulin secretagogues, follow-up should assess not only achievement of the glycemic target, but also possible iatrogenic weight gain, the number of hypoglycemic episodes, dose escalation over time, and the possibility of simplifying or reconsidering the strategy.

A decisive aspect of monitoring is the early clinical response. If, after an adequate period of correct use, appropriate titration, and genuine adherence, a medication produces neither glycemic improvement nor a weight benefit consistent with its expected profile, adherence, lifestyle, drug interactions, alternative diagnoses, eating disorders, and the appropriateness of changing strategy should be assessed promptly. In patients with obesity, follow-up cannot be limited to “seeing whether glycated hemoglobin falls,” but must determine whether treatment is truly modifying the clinical biology of excess adiposity.

When antidiabetic medications are selected with obesity in mind, metabolic prognosis tends to improve not only through lower blood glucose, but through the combined effect on multiple pathogenic pathways. In many cases, compensatory hyperinsulinemia, the need for high doses of exogenous insulin, hepatic steatosis, blood pressure, waist circumference, and progression toward increasingly complex treatment are reduced. This is particularly true when weight loss is achieved early, at a stage when residual beta-cell function is still sufficient to allow meaningful recovery of metabolic control.

The literature of recent years has made it increasingly clear that body weight is not an ancillary variable, but a modifier of the natural history of type 2 diabetes mellitus. In appropriate patients, greater weight losses are associated with higher probabilities of remission or, at least, a marked reduction in treatment requirements. In patients with chronic obesity, multiple complications, and long-standing disease, remission is not always a realistic goal, but slowing progression, limiting the need for insulin, improving daily functioning, and reducing the overall cardiometabolic burden remain clinically highly relevant.

For this reason, a page on antidiabetic medications and obesity cannot be read simply as a comparison of weight-related adverse effects among medications. More fundamentally, it is the point at which diabetes treatment ceases to be only a numerical correction of blood glucose and becomes a strategy aimed at the biological substrate that sustains the disease. In patients with type 2 diabetes mellitus and obesity, this change in perspective is often the difference between sequentially adding medications and constructing treatment that is genuinely consistent with the pathophysiology of the individual case.